Magnitude of intracranial pressure (ICP) elevations and their duration have been associated with worse outcomes in patients with traumatic brain injuries (TBI), however published thresholds for injury vary and uncertainty about these levels has received relatively little attention. In this study, we have analyzed high-resolution ICP monitoring data in 227 adult patients in the CENTER-TBI dataset. Our aim was to identify thresholds of ICP intensity and duration associated with worse outcome, and to evaluate the uncertainty in any such thresholds. We present ICP intensity and duration plots to visualize the relationship between ICP events and outcome. We also introduced a novel bootstrap technique to evaluate uncertainty of the equipoise line. We found that an intensity threshold of 18 ± 4 mmHg (2 standard deviations) was associated with worse outcomes in this cohort. In contrast, the uncertainty in what duration is associated with harm was larger, and safe durations were found to be population dependent. The pressure and time dose (PTD) was also calculated as area under the curve above thresholds of ICP. A relationship between PTD and mortality could be established, as well as for unfavourable outcome. This relationship remained valid for mortality but not unfavourable outcome after adjusting for IMPACT core variables and maximum therapy intensity level. Importantly, during periods of impaired autoregulation (defined as pressure reactivity index (PRx)>0.3) ICP events were associated with worse outcomes for nearly all durations and ICP levels in this cohort and there was a stronger relationship between outcome and PTD. Whilst caution should be exercised in ascribing causation in observational analyses, these results suggest intracranial hypertension is poorly tolerated in the presence of impaired autoregulation. ICP level guidelines may need to be revised in the future taking into account cerebrovascular autoregulation status considered jointly with ICP levels.
Citation: Åkerlund CA, Donnelly J, Zeiler FA, Helbok R, Holst A, Cabeleira M, et al. (2020) Impact of duration and magnitude of raised intracranial pressure on outcome after severe traumatic brain injury: A CENTER-TBI high-resolution group study. PLoS ONE 15(12): e0243427. https://doi.org/10.1371/journal.pone.0243427
Editor: Firas H. Kobeissy, University of Florida, UNITED STATES
Received: October 6, 2020; Accepted: November 21, 2020; Published: December 14, 2020
Copyright: © 2020 Åkerlund et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: CENTER-TBI encourages data sharing, and there is a data sharing statement published: https://center-tbi.eu/data/sharing. Ethical and potential legal restrictions apply due to concerns regarding potential accidental re-identification of patients from such a complex and comprehensive dataset. Data will be available to researchers who provide a study proposal that is approved by the management committee to achieve the aims in the approved proposal. Proposals can be submitted online at https://www.center-tbi.eu/data. A request to access data to control analysis of a published article will be addressed in the same manner. A data access agreement is required and all access must comply with regulatory restrictions imposed on the original study.
Funding: Data used in preparation of this manuscript were obtained in the context of CENTER-TBI, a large collaborative project with the support of the European Union 7th Framework program (EC grant 602150). Additional funding was obtained from the Hannelore Kohl Stiftung (Germany), from OneMind (USA) and from Integra LifeSciences Corporation (USA). FAZ receives research support from the Manitoba Public Insurance (MPI) Neuroscience/TBI Research Endowment, the Health Sciences Centre Foundation Winnipeg, the United States National Institutes of Health (NIH) through the National Institute of Neurological Disorders and Stroke (NINDS), the Canadian Institutes for Health Research (CIHR), the Canadian Foundation for Innovation (CFI), the University of Manitoba Centre on Aging, the University of Manitoba VPRI Research Investment Fund (RIF), and the University of Manitoba Rudy Falk Clinician-Scientist Professorship. DN has also been funded by the Regional Research Agreement (ALF) with Stockholm City Council. Integra LifeSciences provided financial support in respect to data curation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have read the journal’s policy and have the following competing interests: ICM+ is a software created in Brain Physics Laboratory and licensed by Cambridge Enterprise Ltd, UK. PS and MC have financial interest in a fraction of licensing fee. Integra LifeSciences provided financial support in respect to data curation. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no other patents, products in development or marketed products associated with this research to declare.
Traumatic brain injury (TBI) is a major cause of worldwide mortality and morbidity . A key goal of the neurointensive care of the most severely injured patients is to minimize secondary injury through interventions based on the close monitoring of intracranial and systemic physiology.
One of the most important physiological parameters in modern neurocritical care is intracranial pressure (ICP). Supported by a study on the TBI database in Cambridge, UK  the Brain Trauma Foundation (BTF) guidelines state that ICPs above 22 mmHg should be treated as this is associated with increased mortality , and in Europe there is a general consensus that ICP levels above 20 mmHg should be actively managed . Despite this general consensus some studies have shed doubt on the efficacy of ICP monitoring itself [5–8] and question the validity of treating such fixed values. Indeed, without effective management strategies, monitoring by itself cannot improve outcome and heterogeneous treatment strategies may contribute as to explain a lack of established efficacy of monitoring. In particular absolute ‘safe’ levels of ICP have not conclusively been shown, however some attempts have been noted . Additionally, there is no general consensus on what durations of increased ICP levels might be tolerated before harm is caused.
Automatic recording of physiological parameters has been shown to have advantages over manual detection of secondary insults in brain injuries [10, 11]. Continuous recording has made it possible to study the time and pressure dose of ICP in more detail. There has been increasing interest in the impact of the duration of elevated intracranial pressure, both in TBI, and in patients with other than acute brain syndromes. In two single-center studies [12, 13], with 93 and 60 TBI patients respectively, an association was found between an increased pressure-time dose of ICP and poor outcome at 6 months post injury. Similar results have been observed in a cohort of patients with spontaneous subarachnoid haemorrhage, although the underlying pathophysiology is likely to be different from TBI .
An important contribution to understanding the impact of insult duration on outcome was the insult intensity / duration plots described by Güiza et al  which correlated the number of events above increasing thresholds of pressure and time with outcome, visualizing the results on a colour-coded grid. The intensity/duration plot has shed important light on the relation between ICP events and their duration and outcome. Donnelly et al  produced a similar plot albeit with different cut-offs and using data from another cohort of TBI patients. The difference in results between the previous studies implies that ICP tolerability levels might not be universal, but cohort dependent and that the results are associated with some degree of uncertainty. As this uncertainty has not yet been investigated, and these types of plots may be widely used to identify perceived safe levels and durations of raised ICP, it is essential to investigate and establish the certainty of these plots. The aims of this study are thus to investigate the impact of ICP intensity and duration on outcome in the large multi-center cohort in the CENTER-TBI study [17, 18], to examine the impact of cerebrovascular autoregulation status on ICP tolerability and to quantify the certainty/uncertainty of identifiable ICP injury thresholds.
Materials and methods
High-frequency ICP (up to 500 Hz) and arterial blood pressure signals were recorded in 273 patients from 20 different sites participating in the European multi-center study CENTER-TBI, using the software ICM+ (Cambridge Enterprise Ltd, University of Cambridge, UK, versions 22.214.171.124 to 126.96.36.199), or a combination of ICM+ and CNS Monitor (Moberg Research Inc, Ambler, PA, USA), between January 2015 and March 2018. Pressure reactivity Index (PRx), the moving Pearson correlation between ICP and arterial blood pressure, was calculated using standard methodology in ICM+ [19, 20]. Data for the CENTER-TBI study was collected through the Quesgen e-CRF (Quesgen Systems Inc, USA), hosted on the INCF platform and extracted via the INCF Neurobot tool (INCF, Sweden). Version 2.1 of the CENTER-TBI dataset was used in this manuscript.
All patients met the general inclusion criteria for CENTER-TBI (Clinical diagnosis of TBI, clinical indication for CT scan and presentation within 24 hours of injury) and were admitted directly from the ER to the ICU . This study was approved by the CENTER-TBI management committee. The CENTER-TBI study was conducted in accordance with all relevant laws of the European Union if directly applicable or of direct effect and all relevant laws of the country where the Recruiting sites were located, including but not limited to, the relevant privacy and data protection laws and regulations (the “Privacy Law”), the relevant laws and regulations on the use of human materials, and all relevant guidance relating to clinical studies from time to time in force including, but not limited to, the ICH Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) (“ICH GCP”) and the World Medical Association Declaration of Helsinki. Written or oral Informed Consent by the patients or next of kin was obtained, accordingly to the local legislations, for all patients recruited in the Core Dataset of CENTER-TBI and documented in the electronic case report form. In case of oral consent, a written confirmation was requested.
Ethical approval was obtained for each recruiting site. The list of sites, Ethical Committees, approval numbers and approval dates are available online  and ethical approval numbers for sites having recruited patients to the high-resolution sub-study of CENTER-TBI is listed in S1 Appendix.
One-minute averages of ICP data were calculated from 10-second summaries. Data from patients with ventriculostomies was included: External ventricular drains (EVD) were confirmed to have been closed throughout the monitoring period by manual inspection of the ICP waveforms. Data from the day of trauma through day 7 were used for the calculation of ICP burden, based on previous results that mean ICP differs between survivors and non-survivors only the first 7 days post injury .
The Glasgow Outcome Scale Extended (GOS-E) 6 months post injury was used as outcome measure, where 1 indicates death and 8 good recovery without disability. If GOS-E scores at 6 months were missing, a derived GOS-E score was used. A multi-state model created centrally in CENTER-TBI was used if at least one GOS-E value was present outside the pre-specified time window for 6 months. If GOS-E score was missing and could not be imputed, the patient was removed from the final analysis.
Forty-six patients were excluded due to monitoring time shorter than one day (n = 8), missing GOS-E score at 6 months (n = 30) or missing baseline data (n = 8), leaving 227 patients for the final analysis.
Correlations between number of events above thresholds of pressure and time and outcome
The correlation between number of insults above thresholds of ICP and duration was calculated using the insult intensity/duration plot method described previously : The correlations are presented in a grid where each pixel is represented by a colour (blue = positive i.e. better outcome, red = negative, i.e. worse outcome). It corresponds to the Pearson correlation coefficient between mean number of events and GOS-E score for each position on the plot. Each position on the plot represents events above the given ICP level and of a duration. Thresholds of ICP between 10 and 40 mmHg and duration from 5 to 360 minutes were used generating a grid of 11,036 pixels.
PRx, the moving Pearson correlation between ICP and arterial blood pressure, was provided in the measurement files. By averaging PRx for each event, all events were classified into either impaired (PRx > +0.3) or intact (PRx <= 0.3) autoregulation. The cut-off of PRx +0.3 was chosen as threshold, as it previously has been suggested to be associated with worse outcome [2, 23, 24]. Correlations of events with either impaired or intact autoregulation were represented in separate grids. Additionally, we expanded this method as to investigate uncertainty and variability of the results with variations in patient cohorts. This was done using bootstrapping with replacement, generating 1,000 different cohorts. This is a technique where new cohorts are generated by randomly selecting 227 patients. The replacement condition implies that any patient can occur more than once in each sampled cohort. By averaging and calculating standard deviations of the correlations at each grid point, the stability and uncertainty and of the equipoise lines were investigated. By averaging the bootstrapped correlations, a mean transition line was created. Standard deviations of the correlations at each grid point were also calculated, and lines representing correlations +-2 standard deviations from the mean transition line were created.
All analyses were performed using R version 1.1.453 .
Pressure and time dose of ICP (PTD)
In addition to the intensity / duration plots, we investigated the pressure and time dose of ICP (PTD) as a simple alternative measure of insult severity. The PTD was calculated as the area under the curve above thresholds of ICP from 0 to 40 mmHg, as illustrated in Fig 1. Mean doses were calculated for patients with unfavourable/favourable outcome as well as for patients who were dead or alive within 6 months post injury. PTD for intact and impaired autoregulation respectively was also calculated.
An example of how ICP dose as pressure times time dose is represented from a representative patient. The blue-coloured area is the AUC (i.e. the ICP dose) above threshold ICP = 10 mmHg and represents the PTD10.
GOS-E score 5 to 8 was defined as favourable and 1 to 4 as unfavourable outcome. Comparisons of distributions of PTD between groups were performed using the non-parametric Kolmogorov-Smirnov test. A threshold of 0.05 was chosen for statistical significance.
To investigate the relationship between ICP event-burden and PTD towards outcome, we performed multivariable regression analyses, adjusting for known covariates including the IMPACT core variables age, GCS motor score and pupil reactivity [26, 27] and maximum daily therapy intensity level (TIL) score.
Time spent above transition line
To investigate the impact of co-variates on the time spent in areas of the grid with correlation to worse outcome, the time above the transition line was calculated. This was done by first determining the duration of all intensity thresholds at the transition line. For each patient and intensity threshold, the durations of events above this threshold was calculated. If the duration was longer than the duration threshold for that intensity threshold, all ICP values in that episode was regarded to be above the transition line. The duration of all ICP values above the transition line was summarized and divided by total monitoring time.
227 patients with high-resolution ICP measurement for more than one day, over 18 years old and with 6 month GOS-E were included in the final analysis. As presented in Table 1, our cohort consisted of 79% males with a median age of 51 years (IQR 32–64), and 50.2% had no comorbidities at time of injury (ASA class 1), indicating a fairly healthy population before injury. With a median pre-ICU Glasgow Coma Score (GCS) of 6 (IQR 3–10), the cohort can be classified as moderate to severe TBI. 53 patients (23%) underwent a decompressive craniectomy. The median GOS-E at 6 months post injury was 4 (IQR 2–5), Fig 2.
Correlations between number of insults and outcome
The correlation between number of events against ICP and duration for the high-resolution cohort is presented in Fig 3A. A black transition curve divides the surface into two areas: A small blue area in the bottom left corner where number of events more frequently occur in patients with better outcome and a large red-orange area where number of events are associated with worse outcome. The transition curve represents a no correlation region between number of events and outcome.
Red indicates that ICP events are correlated to worse outcome at that specific ICP level and event duration on the map. A. The black line represents the transition line, where there is no correlation between number of events above threshold and outcome. B. The black line represents the mean transition line of 1000 bootstraps. The white lines represent the mean transition line +2 SD, while the grey line represents the mean transition line -2 SD. Above, and to the right, of the white line, there is a high degree of statistical certainty of events being associated with worse outcome, whereas below the grey line, the statistical certainty is high that events are not associated with harm.
We investigated the stability of the results by applying bootstrapping with replacement to create 1,000 different populations of 227 patients (same sample size as our cohort) to give the population dependent variability of the transition line (corresponding to correlation coefficient 0 towards GOS-E). Ten randomly selected bootstrapped correlation plots are presented in S1 Fig to illustrate how the results are affected by different cohort constitutions. Mean correlations, with the mean transition line in black (worse vs. better outcome), plus/minus two standard deviations (white), are presented in Fig 3B.
To investigate the impact of cerebral autoregulation status on tolerability of ICP events, all events were stratified according to either intact (mean PRx <= 0.3) or impaired (mean PRx > 0.3) autoregulation, Fig 4A and 4B. All patients had, to different extents, both events with intact and impaired autoregulation, Fig 5, and 24.9% of the total monitoring time had a mean PRx > 0.3, indicating impaired autoregulation. In case of impaired autoregulation (Fig 4B), no threshold for tolerable ICP intensities and durations could be found.
Orange / red areas indicates areas where ICP levels and event durations are associated with worse outcomes. The transition line, i.e. where there is no correlation between number of events and outcome, is drawn in black. All patients contribute some data to both plots, the degree however depending on the extent of their intact vs. impaired autoregulation. A) Intact autoregulation (mean PRx <= 0.3), B) Impaired autoregulation (mean PRx > 0.3).
All patients had both episodes of impaired and intact autoregulation, but to different extents.
In the univariable regression analysis, the time spent above the transition line was a statistically significant predictor of both unfavourable outcome and 6-month mortality, OR = 2.24 (95% CI 1.02–4.99, p = 0.046) and OR = 4.18 (95% CI 1.64–11.16, p = 0.003). When adjusted for the IMPACT core variables and maximum daily TIL, time above the transition line remained statistically significantly associated with mortality OR = 3.56 (95% CI 1.14–11.74, p = 0.032), but not with unfavourable outcome OR = 1.37 (95% CI 0.51–3.76, p = 0.533). A full summary of the regression is presented in Table C in S2 Appendix.
Pressure and time dose of ICP
The mean PTD above thresholds of 0 to 40 mmHg are presented for each category of GOS-E in Fig 6. Patients with unfavourable outcome had a significantly higher mean PTD above 20 and 25 mmHg compared to patients with favourable outcome, Fig 7A and Table 2, with PTD20 being 232.9 (± 750.8) vs 35.1 (± 64.5) mmHg·h respectively (p = 0.014).
The group mean PTD was higher for patients who had died within 6 months post injury, while the mean doses were similar for GOS-E 3 to 8 outcomes.
On average, patients who died within 6 months post injury had a statistically significantly higher PTD above all ICP thresholds of 10 mmHg and above compared to survivors, Fig 7B and Table 2. The mean PTD above 20 mmHg was 493.4 (± 1125.6) vs 43.8 (± 84.7) mmHg·h (p = 0.004).
PTD was also calculated separately for periods with intact (PTDintact) and impaired (PTDimpaired) autoregulation, Fig 8, Tables 3 and 4. There was no significant difference in mean PTD between favourable and unfavourable outcome at any ICP threshold when stratified by intact or impaired autoregulation, Fig 8A and Table 3.
Additionally, autoregulation stratified mortality cohorts showed similar patterns to that of unstratified mortality but with a generally stronger association towards outcome. PTDintact and PTDimpaired stratified cohorts were significant related to mortality above all thresholds of ICP, Fig 8C and 8D and Table 4. The mean PTD of intact autoregulation above 20 mmHg was 66.7 (± 150.6) vs 25.0 (± 64.5) mmHg·h for non-survivors and survivors, respectively (p = 0.0037), and mean PTDimpaired above 20 mmHg was 414.9 (± 1035.6) and 12.8 (± 20.1), respectively (p<0.001).
When adjusted for the IMPACT core variables (age, GCS motor score at baseline and pupil reactivity) and maximum daily TIL, PTD was not an independent predictor of favourable outcome, OR = 1.0 (95% CI 0.99–1.00, p = 0.390), but still a significant predictor for 6 month mortality, OR = 1.0 (95% CI 1.00–1.01, p = 0.012), Table D in S2 Appendix. Neither PTDintact nor PTDimpaired were retained as significant predictors of 6-month mortality in a multivariable regression model, OR = 1.00 (95% CI 0.99–1.01, p = 0.238) and 1.02 (1.00–1.02, p = 0.236), respectively.
In this study we investigate the relationship between time-dependent ICP insults and outcome. We confirm findings of the Insult intensity/duration plot methodology, albeit finding lower acceptable ICP levels, in a new multicentre cohort and also investigate simpler pressure-time-dose measures. Importantly, we also introduce a novel bootstrap methodology to assess the certainty/uncertainty of the transition line of the correlation plot, above which there is an increased correlation between number of events and worse outcome. We believe this is a necessary extension to the insult intensity plots in order to interpret them with confidence. Additionally, we investigate relations of potential ICP vulnerability during periods of intact and impaired autoregulation suggesting that safe ICP levels may vary depending on autoregulatory status.
The overall pattern concerning association of ICP events and worse outcome in our study is similar to previously published results: However, we find lower limits for acceptable ICPs. In contrast to ICP thresholds, there is a higher degree of uncertainty in what duration of insult is associated with harm; the length of ICP events that are associated with worse outcome were more variable and population dependent. As indicated in Fig 3B, ICP levels above 18 ±4 mmHg for five minutes or longer are associated with worse outcome whereas another threshold at 13 mmHg with a wide time uncertainty is seen.
Above the +2 SD line there is a strong association between number of events at all levels of intensity and duration of ICP and worse outcome, and the time spent in this zone is strongly correlated both to 6-month mortality and unfavourable outcome. It can also be concluded that it is fairly certain that events to the right of the white line (mean transition line +2 SD) are associated with worse outcome. This corresponds to ICP events above 22 mmHg longer than 5 minutes and above 16 mmHg for longer than 60 minutes. As a comparison, previously suggested cut-offs from Güiza et al are 35 mmHg for 5 minutes or 20 mmHg for 37 minutes  and from Donnelly et al an ICP of 20 mmHg for longer than 13 minutes . However, in both cases, correlations between 5-level GOS (rather than GOS-E as in this work) and ICP events were analysed. The first mentioned cohort was similar to ours with respect to age, admission GCS and cerebrovascular reactivity status, however the CENTER-TBI high-resolution cohort had a worse outcome at the group level. This may be attributable to numerous possible factors and could cause a general shift in our curves. To investigate if the difference in results were not due to using different outcome measures (GOS vs. GOS-E), we reproduced the same analysis with GOS as an outcome measure, with almost no difference in result (S3 Fig). It is important to mention that these results assume a linear relationship between number of events above thresholds and GOS-E score, which might be an inappropriate approximation and needs to be explored further. In summary, we find that although the pattern is similar between cohorts, absolute levels differ, supporting our effort to investigate certainty/uncertainty on regions of the map before defining or suggesting generalized cut-offs.
As with any observational analysis, the question is whether our results represent causation (i.e. if reducing ICP to lower insult levels in a timely way could affect outcome) or simply association, and the methods used in this study cannot distinguish between the two. However, it is biologically plausible that short periods of higher levels of ICP could be causally related to outcome although perhaps identified thresholds for longer time periods might represent associations at a cohort level as uncertainty is higher along this direction of the map.
The association between ICP intensity / duration and outcome are likely to be affected by any treatment directed at lowering of ICP. An attempt to adjust for these factors was done by including a measure of therapy intensity level in a multivariable regression model of time in red-orange zone and its association on outcome. This analysis suggested that the time above the transition line is a statistically significant predictor for death but not for unfavourable outcome.
Decompressive craniectomy (DC) is an intervention most likely affecting intracranial pressure levels as well as tolerability and reactivity. In the analysis, the 53 patients in our cohort who underwent DC were included. Including these patients might be regarded a limitation, particularly when previous studies have been inconsistent in whether PRx is affected or not [28, 29]. However, it is biologically plausible that ICP elevations are harmful to the brain per se, no matter whether DC has been performed or not. A separate analysis of this group alone could not be performed due to limited sample size and a seemingly greater inter-individual variation of ICP tolerability. A sensitivity analysis, excluding these patients is presented in S2 Fig yielded qualitatively similar results.
Broadly speaking, although our results suggest a somewhat lower threshold of ICP elevations our results are not dissimilar to both the BTF recommendations (ICP target below 22 mmHg ) and European neurointensive care practice (ICP 20 mmHg ) especially if bearing in mind that the error of measurement for ICP measurement is of the order of 1.5 mmHg .
Importantly, we also demonstrate that ICP tolerability appears highly dependent on cerebrovascular reactivity, Fig 4, and there appears to be no threshold for tolerable ICP during periods of disrupted autoregulation. In the case of intact autoregulation, our results suggest that an ICP above 19 mmHg for 5 minutes or longer or 15 mmHg for 50 minutes or longer was strongly associated with worse outcome. The finding that ICP tolerability may be dependent on cerebral autoregulation status is in line with previous studies which have suggested that autoregulation status or individualized ICP thresholds derived from autoregulation status seem to better predict outcome than fixed ICP levels [9, 31]. A similar pattern was also found by Güiza . Further, it is biologically plausible that in the absence of intact autoregulation, the brain is left vulnerable and unable to compensate for global and regional changes in cerebral perfusion over time. Attempts to determine individual baseline ICPs by correlating the PRx to ICP to identify individualized ICP thresholds has been done by both Lazaridis et al and Zeiler et al [9, 31], an approach that needs to be further investigated in future studies. Several recent publications have also pointed at cerebrovascular reactivity being more important than fixed ICP thresholds in limiting secondary injuries [32–34]. It has also been suggested that it is the cerebral perfusion pressure (CPP) rather than the ICP that represent the true burden of secondary insult. The purpose of this study, however, was to investigate the impact of ICP, and the impact of treatments to optimise care (e.g. targeting CPPopt ) still need to be explored.
Our study and previous studies indicate that avoiding ICP peaks above 20 mmHg appears justified in aggregate across all patients, however during periods of autoregulatory loss, no safe limit can be identified.
The role of pressure times time dose
The PTD may be an additional, simple, measure of ICP tolerability and has been suggested as a predictor for mortality and unfavourable outcome by several authors, especially doses of ICP 20 mmHg and above. However, methodology and choice of threshold for PTD has been varied between studies, making comparison difficult [12–14, 36]. As seen in Fig 6, we also identify a relationship between higher PTD and worse outcome. A statistical difference was identified between a PTD above 20 mmHg and unfavourable outcome, and that of PTD above ICP 10 mmHg and mortality. This may not represent absolute levels of ICP but a general association that is merely stronger in relation to mortality vs. favourable/unfavourable outcome. However, an association that, when adjusted for IMPACT core variables and TIL, remained significant for mortality but not unfavourable outcome (S2 Appendix Table B). Care is required in the final interpretation of PTD cut-off levels as ICP vulnerability might be expected to change over time with changing pathophysiology, as well as the individual metabolic states of the brain, and a next step would be to investigate the temporal evolution of ICP and ICP vulnerability.
Our results differ from previously reported PTD, which may reflect differences in the details of the methods used in its calculation with time windows from 24 hours up to total monitoring time as well as different time resolutions of ICP measurements. There is no choice that is clearly superior as a description of the ICP secondary insult burden. Nevertheless, despite these discrepancies, a relationship between PTD and outcome appears robust across studies.
In summary, we identify a clear relationship between high doses of ICP and mortality but not for favourable/unfavourable outcome. However, we also identify clear correlations between number of events above thresholds of ICP intensity, even with short durations, and worse outcome. In aggregate this could suggest that peaks of ICP elevation might in themselves be harmful. We hypothesize, given the greater uncertainty in the time dimension, that short periods of raised ICP may be causal of injury and long periods of moderately high ICP may be association with injury severity. If so, ICP variability may also be related to outcome and worth further future investigation.
Advantages, limitations and future directions
A major strength of this study is its multi-center design where more than 220 patients from 20 sites across Europe were included. This, in combination with the applied bootstrapping technique minimizes potential confounding effects of site-specific treatments of severe TBI.
Some limitations must be noted. It is important to stress that the relationship which we have established between ICP magnitude and duration and outcome is associative, and none of the methods used in this paper can conclusively establish a causative relation. We have also made the assumption of a linear relationship, and cannot exclude that a non-linear model would make a better fit. Treatment of patients with severe TBI is complex, and the impact of treatments on outcome is not yet fully understood. Although we have adjusted for treatments in multivariable regression models, we have not been able to show if they act as confounders or are causative in the relationship of ICP and outcome. Furthermore, ICP vulnerability might change over time, something we have not taken into consideration in this study.
It would be of great interest to further investigate aspects of the temporal evolution of ICP and ICP vulnerability as well as to better establish potential causality in relation to outcome. Our results lead us to hypothesize that short periods of ICP elevations may be causal of injury and more extended periods of moderate elevation may be more associated to TBI severity. Future studies should focus on exploring the use of emerging techniques to evaluate causality with mathematical modelling and to investigate the impact of ICP variability on outcome.
We have explored the relations of ICP towards outcome, employing several metrics of burden. We identify ICP limits and event durations associated with worse outcome, and importantly the uncertainty of such estimates. We find 18 mmHg to be the most probable safe ICP limit even for short durations. Given an uncertainty of ± 4 mmHg (± 2 SD), 22 mmHg can be identified as a limit that is with a high certainty related to worse outcome, and thus in concert with current BTF guidelines. However, it is lower than earlier event-duration plot studies. Although the adjusted ICP pressure time dose was strongly correlated to mortality, short periods of high ICP appear more confidently related to worse outcome than long periods of moderately high ICP leading us to hypothesize that the relation of burden towards outcome at lower ICP levels may be an association with injury severity, but shorter periods of elevated ICP may be more causative of injury. Additionally, we have found that ICP tolerability appears highly dependent on the cerebral autoregulation status where, in the case of impaired cerebrovascular reactivity, no safe ICP levels could be identified, suggesting that safe limits may need to be related to current autoregulatory status in the future.
S1 Appendix. List of ethical approvals for sites included in the high-resolution CENTER-TBI sub-study.
S1 Fig. Correlation between number of events above thresholds of intracranial pressure and duration and outcome (GOS-E score), ten illustrative bootstraps with replacement, sample size 209.
The black line represents the transition line, above which there is a correlation between more events and worse outcome. As seen, the shape and values of the transition line is dependent on the patient selection.
S2 Fig. Correlation between number of events above thresholds of intracranial pressure and duration and outcome (GOS-E score).
A. All patients. B. All patients who has not undergone decompressive craniectomy. C. All patients with other monitors than extra-ventricular drain. D. All patients who has not undergone decompressive craniectomy and do not have an extra-ventricular drain.
S3 Fig. Correlation between number of events above thresholds of intracranial pressure and duration and outcome (GOS score).
S4 Fig. Distribution of monitoring time in days, stratified by 6 month mortality.
The authors would like to thank the CENTER-TBI High Resolution ICU Sub-Study Participants and Investigators for taking part in the collection of data:
Group leader: Professor Nino Stocchetti: email@example.com
Audny Anke 1, Ronny Beer 2, Bo-Michael Bellander3, Erta Beqiri4, Andras Buki5, Manuel Cabeleira6, Marco Carbonara7, Arturo Chieregato4, Giuseppe Citerio8, 9, Hans Clusmann10, Endre Czeiter11, Marek Czosnyka6, Bart Depreitere12, Ari Ercole13, Shirin Frisvold14, Raimund Helbok2, Stefan Jankowski15, Danile Kondziella16, Lars-Owe Koskinen17, Ana Kowark18, David K. Menon13, Geert Meyfroidt19, Kirsten Moeller20, David Nelson3, Anna Piippo-Karjalainen21, Andreea Radoi22, Arminas Ragauskas23, Rahul Raj21, Jonathan Rhodes24, Saulius Rocka23, Rolf Rossaint18, Juan Sahuquillo22, Oliver Sakowitz25, 26, Peter Smielewski6, Nino Stocchetti27, Nina Sundström28, Riikka Takala29, Tomas Tamosuitis30, Olli Tenovuo31, Andreas Unterberg26, Peter Vajkoczy32, Alessia Vargiolu8, Rimantas Vilcinis33, Stefan Wolf34, Alexander Younsi26, Frederick A. Zeiler13,35
1 Department of Physical Medicine and Rehabilitation, University hospital Northern Norway
2 Department of Neurology, Neurological Intensive Care Unit, Medical University of Innsbruck, Innsbruck, Austria
3 Department of Neurosurgery & Anesthesia & intensive care medicine, Karolinska University Hospital, Stockholm, Sweden
4 NeuroIntensive Care, Niguarda Hospital, Milan, Italy
5 Department of Neurosurgery, Medical School, University of Pécs, Hungary and Neurotrauma Research Group, János Szentágothai Research Centre, University of Pécs, Hungary
6 Brain Physics Lab, Division of Neurosurgery, Dept of Clinical Neurosciences, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK
7 Neuro ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
8 NeuroIntensive Care Unit, Department of Anesthesia & Intensive Care, ASST di Monza, Monza, Italy
9 School of Medicine and Surgery, Università Milano Bicocca, Milano, Italy
10 Department of Neurosurgery, Medical Faculty RWTH Aachen University, Aachen, Germany
11 Department of Neurosurgery, University of Pecs and MTA-PTE Clinical Neuroscience MR Research Group and Janos Szentagothai Research Centre, University of Pecs, Hungarian Brain Research Program (Grant No. KTIA 13 NAP-A-II/8), Pecs, Hungary
12 Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium
13 Division of Anaesthesia, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK
14 Department of Anesthesiology and Intensive care, University Hospital Northern Norway, Tromso, Norway
15 Neurointensive Care, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
16 Departments of Neurology, Clinical Neurophysiology and Neuroanesthesiology, Region Hovedstaden Rigshospitalet, Copenhagen, Denmark
17 Department of Clinical Neuroscience, Neurosurgery, Umeå University, Umeå, Sweden
18 Department of Anaesthesiology, University Hospital of Aachen, Aachen, Germany
19 Intensive Care Medicine, University Hospitals Leuven, Leuven, Belgium
20 Department Neuroanesthesiology, Region Hovedstaden Rigshospitalet, Copenhagen, Denmark
21 Helsinki University Central Hospital, Helsinki, Finland
22 Department of Neurosurgery, Vall d’Hebron University Hospital, Barcelona, Spain
23 Department of Neurosurgery, Kaunas University of technology and Vilnius University, Vilnius, Lithuania
24 Department of Anaesthesia, Critical Care & Pain Medicine NHS Lothian & University of Edinburg, Edinburgh, UK
25 Klinik für Neurochirurgie, Klinikum Ludwigsburg, Ludwigsburg, Germany
26 Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany
27 Department of Pathophysiology and Transplantation, Milan University, and Neuroscience ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy
28 Department of Radiation Sciences, Biomedical Engineering, Umea University, Umea, Sweden
29 Perioperative Services, Intensive Care Medicine, and Pain Management, Turku University Central Hospital and University of Turku, Turku, Finland
30 Neuro-intensive Care Unit, Kaunas University of Health Sciences, Kaunas, Lithuania
31 Rehabilitation and Brain Trauma, Turku University Central Hospital and University of Turku, Turku, Finland
32 Neurologie, Neurochirurgie und Psychiatrie, Charité–Universitätsmedizin Berlin, Berlin, Germany
33 Department of Neurosurgery, Kaunas University of Health Sciences, Kaunas, Lithuania
34 Department of Neurosurgery, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
35 Section of Neurosurgery, Department of Surgery, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada
- 1. Maas AIR, Menon DK, Adelson PD, Andelic N, Bell MJ, Belli A, et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurol. 2017;16: 987–1048. pmid:29122524
- 2. Sorrentino E, Diedler J, Kasprowicz M, Budohoski KP, Haubrich C, Smielewski P, et al. Critical Thresholds for Cerebrovascular Reactivity After Traumatic Brain Injury. Neurocrit Care. 2012;16: 258–266. pmid:21964774
- 3. Carney N, Totten AM, O’Reilly C, Ullman JS, Hawryluk GWJ, Bell MJ, et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery. 2016. pmid:27654000
- 4. Cnossen MC, Huijben JA, Van Der Jagt M, Volovici V, Van Essen T, Polinder S, et al. Variation in monitoring and treatment policies for intracranial hypertension in traumatic brain injury: a survey in 66 neurotrauma centers participating in the CENTER-TBI study. Crit Care. 2017;21.
- 5. Farahvar A, Gerber LM, Chiu Y-L, Carney N, Härtl R, Ghajar J. Increased mortality in patients with severe traumatic brain injury treated without intracranial pressure monitoring. J Neurosurg. 2012;117: 729–734. pmid:22900846
- 6. Chesnut RM, Temkin N, Carney N, Dikmen S, Rondina C, Videtta W, et al. A Trial of Intracranial-Pressure Monitoring in Traumatic Brain Injury. n engl j med. 2012;36726367: 2471–81. pmid:23234472
- 7. Shafi S, Diaz-Arrastia R, Madden C, Gentilello L. Intracranial Pressure Monitoring in Brain-Injured Patients is Associated With Worsening of Survival. J Trauma Inj Infect Crit Care. 2008;64: 335–340. pmid:18301195
- 8. Aiolfi A, Elizabeth Benjamin B, Desmond Khor B, Kenji Inaba B, Lam L, Demetrios Demetriades B. Brain Trauma Foundation Guidelines for Intracranial Pressure Monitoring: Compliance and Effect on Outcome. World J Surg. 2017;41. pmid:28188356
- 9. Lazaridis C, Desantis SM, Smielewski P, Menon DK, Hutchinson P, Pickard JD, et al. Patient-specific thresholds of intracranial pressure in severe traumatic brain injury: Clinical article. J Neurosurg. 2014;120: 890–900. pmid:24506248
- 10. Zanier ER, Ortolano F, Ghisoni L, Colombo A, Losappio S, Stocchetti N. Intracranial pressure monitoring in intensive care: Clinical advantages of a computerized system over manual recording. Crit Care. 2007;11: 1–6. pmid:17233895
- 11. Hemphill JC, Barton CW, Morabito D, Manley GT. Influence of data resolution and interpolation method on assessment of secondary brain insults in neurocritical care. Physiol Meas. 2005;26: 373–386. pmid:15886433
- 12. Vik A, Nag T, Fredriksli OA, Skandsen T, Moen KG, Schirmer-Mikalsen K, et al. Relationship of “dose” of intracranial hypertension to outcome in severe traumatic brain injury. J Neurosurg. 2008;109: 678–684. pmid:18826355
- 13. Sheth KN, Stein DM, Aarabi B, Hu P, Kufera JA, Scalea TM, et al. Intracranial pressure dose and outcome in traumatic brain injury. Neurocrit Care. 2013;18: 26–32. pmid:23055087
- 14. Magni F, Pozzi M, Rota M, Vargiolu A, Citerio G. High-Resolution Intracranial Pressure Burden and Outcome in Subarachnoid Hemorrhage. Stroke. 2015;46: 2464–2469. pmid:26243224
- 15. Güiza F, Depreitere B, Piper I, Citerio G, Chambers I, Jones PA, et al. Visualizing the pressure and time burden of intracranial hypertension in adult and paediatric traumatic brain injury. Intensive Care Med. 2015;41: 1067–1076. pmid:25894624
- 16. Donnelly J, Güiza F, Depreitere B, Meyfroidt G, Czosnyka M, Smielewski P. Visualizing the pressure-time burden of elevated intracranial pressure after severe TBI—a retrospective confirmatory study. British Journal of Anaesthesia; 2020.
- 17. Maas AIR, Menon DK, Steyerberg EW, Citerio G, Lecky F, Manley GT, et al. Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI): A Prospective Longitudinal Observational Study. Neurosurgery. 2015;76: 67–80. pmid:25525693
- 18. Steyerberg EW, Wiegers E, Sewalt C, Buki A, Citerio G, De Keyser V, et al. Case-mix, care pathways, and outcomes in patients with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, cohort study. Lancet Neurol. 2019;18: 923–934. pmid:31526754
- 19. Czosnyka M, Smielewski P, Kirkpatrick P, Laing RJ, Menon D, Pickard JD. Continuous assessment of the cerebral vasomotor reactivity in head injury. Neurosurgery. 1997;41: 11–19. pmid:9218290
- 20. Pressure reactivity index (PRx). 2019 [cited 19 Nov 2019]. http://cppopt.org/prx/
- 21. CENTER-TBI. CENTER-TBI Ethical Approval. https://www.center-tbi.eu/project/ethical-approval
- 22. Adams H, Donnelly J, Czosnyka M, Kolias AG, Helmy A, Menon DK, et al. Temporal profile of intracranial pressure and cerebrovascular reactivity in severe traumatic brain injury and association with fatal outcome: An observational study. PLoS Med. 2017;14: e1002353. pmid:28742817
- 23. Donnelly J, Czosnyka M, Adams H, Robba C, Steiner LA, Cardim D, et al. Individualizing Thresholds of Cerebral Perfusion Pressure Using Estimated Limits of Autoregulation. Crit Care Med. 2017;45: 1464–1471. pmid:28816837
- 24. Zeiler FA, Donnelly J, Smielewski P, Menon DK, Hutchinson PJ, Czosnyka M. Critical Thresholds of Intracranial Pressure-Derived Continuous Cerebrovascular Reactivity Indices for Outcome Prediction in Noncraniectomized Patients with Traumatic Brain Injury. J Neurotrauma. 2018;35: 1107–1115. pmid:29241396
- 25. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2018. https://www.r-project.org/
- 26. Maas AIR, Harrison-Felix CL, Menon D, Adelson PD, Balkin T, Bullock R, et al. Standardizing data collection in traumatic brain injury. J Neurotrauma. 2011;28: 177–87. pmid:21162610
- 27. Steyerberg EW, Mushkudiani N, Perel P, Butcher I, Lu J, Mchugh GS, et al. Predicting Outcome after Traumatic Brain Injury: Development and International Validation of Prognostic Scores Based on Admission Characteristics. 2008 [cited 24 May 2018].
- 28. Zeiler FA, Aries M, Cabeleira M, Van Essen TA, Stocchetti N, Menon DK, et al. Statistical Cerebrovascular Reactivity Signal Properties after Secondary Decompressive Craniectomy in Traumatic Brain Injury: A CENTER-TBI Pilot Analysis. J Neurotrauma. 2020;37: 1306–1314. pmid:31950876
- 29. Timofeev I, Czosnyka M, Nortje J, Smielewski P, Kirkpatrick P, Gupta A, et al. Effect of decompressive craniectomy on intracranial pressure and cerebrospinal compensation following traumatic brain injury. J Neurosurg. 2008;108: 66–73. pmid:18173312
- 30. Zacchetti L, Magnoni S, Di Corte F, Zanier ER, Stocchetti N. Accuracy of intracranial pressure monitoring: Systematic review and meta-analysis. Crit Care. 2015;19: 1–8.
- 31. Zeiler FA, Ercole A, Cabeleira M, Beqiri E, Zoerle T, Carbonara M, et al. Patient-specific ICP Epidemiologic Thresholds in Adult Traumatic Brain Injury. J Neurosurg Anesthesiol. 2019; Publish Ah: 1–11.
- 32. Smith M, Maas AIR. An algorithm for patients with intracranial pressure monitoring: filling the gap between evidence and practice. Intensive Care Med. 2019. pmid:31616963
- 33. Nourallah B, Zeiler FA, Calviello L, Smielewski P, Czosnyka M, Menon DK. Critical thresholds for intracranial pressure vary over time in non-craniectomised traumatic brain injury patients. Acta Neurochir (Wien). 2018;160: 1315–1324. pmid:29732476
- 34. Helbok R, Meyfroidt G, Beer R. Intracranial pressure thresholds in severe traumatic brain injury: Con: The injured brain is not aware of ICP thresholds! Intensive Care Med. 2018;44: 1318–1320. pmid:29978388
- 35. Steiner LA, Czosnyka M, Piechnik SK, Smielewski P, Chatfield D, Menon DK, et al. Continuous monitoring of cerebrovascular pressure reactivity allows determination of optimal cerebral perfusion pressure in patients with traumatic brain injury. Crit Care Med. 2002;30: 733–738. pmid:11940737
- 36. Kahraman S, Dutton RP, Hu P, Xiao Y, Aarabi B, Stein DM, et al. Automated measurement of “pressure times time dose” of intracranial hypertension best predicts outcome after severe traumatic brain injury. J Trauma—Inj Infect Crit Care. 2010;69: 110–118. pmid:20038855